Abstract:The Wilms' tumor 1 (WT1) gene is one of the regulating factors in cell proliferation and development. It is a double-functional gene: an oncogene and a tumor suppressor. This gene was found to be highly expressed in many leukemic cell lines and in patients with acute myeloid leukemia. In the present study, we demonstrated that the WT1 gene was commonly expressed in leukemic cell lines apart from U937 cells. The K562 cell line which expresses WT1 at a high level (mRNA and protein) was used in the entire experiment. By MTT and colony formation assays, we found that curcumin, an inhibitor of the WT1 protein, inhibited cell proliferation and clonogenicity in a time- and dose-dependent manner. It also caused cell cycle arrest at the G2/M phase. We then designed specific short hairpin RNAs (shRNAs) which could downregulate WT1 by 70-80% at the mRNA and protein levels. Reduction in the WT1 levels attenuated the proliferative ability and clonogenicity. Cell cycle progression analysis indicated that the proportion of cells in the G0/G1 phase increased while the proportion in the S phase decreased distinctively. ChIP-DNA selection and ligation (DSL) experiment identified a cohort of genes whose promoters are targeted by WT1. These genes were classified into different cellular signaling pathways using MAS software and included the Wnt/β-catenin pathway, MAPK signaling pathway, apoptosis pathway, and the cell cycle. We focused on the Wnt/β-catenin signaling pathway, and compared expression of several genes in the K562 cells transfected with the control shRNA and WT1-specific shRNA. β-catenin, an important gene in the Wnt canonical pathway, was downregulated after WT1 RNAi. Target genes of β-catenin which participate in cell proliferation and cell cycle regulation, such as CCND1 and MYC, were also significantly downregulated. Collectively, these data suggest that WT1 functions as an oncogene in leukemia cells, and one important mechanism is regulation of the Wnt/β-catenin pathway.

Long Non-coding Wilms Tumor 1 Antisense RNA in the Development and Progression of Malignant Tumors

High Wilms' Tumor 1 Mrna Expression Correlates with Basal-Like and Erbb2 Molecular Subtypes and Poor Prognosis of Breast Cancer

Long Non-Coding RNA XIST Promotes Wilms Tumor Progression Through the Mir-194-5p/yap Axis.

Decreased Expression of Long Non-Coding Rna Wt1-As Promotes Cell Proliferation and Invasion in Gastric Cancer

Comprehensive Analysis of a Long Noncoding RNA-Associated Competing Endogenous RNA Network in Wilms Tumor

Loss of long noncoding RNA WT 1-AS is associated with better survival in early stage of cervical cancer

A Survival-Related Competitive Endogenous RNA Network of Prognostic Lncrnas, Mirnas, and Mrnas in Wilms Tumor

Long non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression

Wilms' tumor 1 gene in hematopoietic malignancies: clinical implications and future directions

Comprehensive analysis of long non‑coding RNA using an associated competitive endogenous RNA network in Wilms tumor

Comprehensive Analysis of the Long Non-Coding RNA-associated Competitive Endogenous RNA Network Reveals Novel Prognostic Biomarkers in Wilms' Tumor.

Role of the Wilms' Tumor 1 Gene in the Aberrant Biological Behavior of Leukemic Cells and the Related Mechanisms.

Overexpression of Lncrna WWTR1‐AS1 Associates with Tumor Aggressiveness and Unfavorable Survival in Head‐neck Squamous Cell Carcinoma

Promising Long Noncoding RNA DLX6-AS1 in Malignant Tumors

Oncogenic Roles and Mechanisms of Lncrna AGAP2-AS1 in Human Solid Tumors.

Biological functions and clinical significance of long noncoding RNAs in bladder cancer

WT1 Promotes Invasion of NSCLC Via Suppression of CDH1

The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism

WT1 promotes invasion of NSCLC via suppression of CDH1.

Targeting Long Non-coding RNA to Therapeutically Regulate Gene Expression in Cancer.

Advances in the study of antisense long‐stranded non‐coding RNAs in tumors (Review)